MEETINGS & COURSES
Find a meeting
 FEATURED MEETINGS
  Rome 2010
  Kiawah Eye 2010
  OSN New York 2010
  Hawaiian Eye 2011
  Retina 2011
 
Breaking Influenza
A (H1N1) Updates
OPHTHALMIC BUSINESS
Posted on the OSN SuperSite April 26, 2007
ISTA reports 91% increase in first quarter revenue
Submit a Comment Submit a Comment Print  Print Email this page to a friend  E-mail

IRVINE, Calif. — ISTA Pharmaceuticals reported net revenue for the first quarter totaled $10.3 million, a 91% increase over net revenue for the first quarter 2006, according to a press release from the company.

Net revenue from sales of Xibrom (bromfenac ophthalmic solution 0.09%) increased 150% to total $7 million. Revenue from sales of Istalol (timolol maleate 0.5%) increased 29% to total $2.2 million, while revenue from Vitrase (hyaluronidase) sales increased 25% to total $1 million.

Despite increased revenue, ISTA reported a net loss for the quarter of $11.5 million, or $0.44 per share, compared with a net loss of $10.7 million for the first quarter 2006.

The OSN SuperSite is intended for physician use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will the OSN SuperSite be used for medical advice to patients.

There are no comments for this article. Be the first to comment.

Your comment

Name:
Comments:
SEE ALSO
Roche posts 8% increase in sales for 2009
Posted on the OSN SuperSite February 8, 2010
Paloma Pharmaceuticals initiates phase 1 study of anti-angiogenic agent for neovascular AMD
Posted on the OSN SuperSite February 5, 2010
Allergan reports $1.206 billion in total net sales for fourth quarter
Posted on the OSN SuperSite February 5, 2010
MULTIMEDIA
Ozurdex injection technique
Ozurdex injection technique

Submitted by: Allergan; Sunil Gupta, MD (2/4/2010).

more

COVER STORIES
Endothelial keratoplasty challenges the primacy of full-thickness transplantation
Corneal transplantation has long been the preferred treatment for pathologies that respond poorly to topical medications or implants.
more